Voloridge Investment Management LLC Takes Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Voloridge Investment Management LLC acquired a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 119,015 shares of the company's stock, valued at approximately $2,804,000. Voloridge Investment Management LLC owned approximately 0.12% of Dyne Therapeutics as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. KBC Group NV raised its stake in shares of Dyne Therapeutics by 45.3% in the 4th quarter. KBC Group NV now owns 3,135 shares of the company's stock valued at $74,000 after buying an additional 978 shares in the last quarter. Summit Investment Advisors Inc. raised its stake in shares of Dyne Therapeutics by 9.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company's stock valued at $203,000 after buying an additional 721 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in shares of Dyne Therapeutics in the 4th quarter valued at $257,000. Magnetar Financial LLC acquired a new position in shares of Dyne Therapeutics in the 4th quarter valued at $263,000. Finally, E Fund Management Co. Ltd. raised its stake in shares of Dyne Therapeutics by 11.8% in the 4th quarter. E Fund Management Co. Ltd. now owns 11,848 shares of the company's stock valued at $279,000 after buying an additional 1,249 shares in the last quarter. Institutional investors and hedge funds own 96.68% of the company's stock.

Wall Street Analyst Weigh In

DYN has been the topic of several analyst reports. HC Wainwright lowered their target price on shares of Dyne Therapeutics from $46.00 to $38.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Evercore ISI initiated coverage on shares of Dyne Therapeutics in a report on Thursday. They issued an "outperform" rating and a $46.00 target price on the stock. BMO Capital Markets initiated coverage on shares of Dyne Therapeutics in a report on Wednesday, March 12th. They issued an "outperform" rating and a $50.00 target price on the stock. JPMorgan Chase & Co. lowered their target price on shares of Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating on the stock in a report on Friday, March 21st. Finally, Scotiabank initiated coverage on shares of Dyne Therapeutics in a report on Friday, March 7th. They issued a "sector outperform" rating and a $50.00 target price on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $47.15.

Dyne Therapeutics Stock Down 3.4%

NASDAQ:DYN traded down $0.42 during mid-day trading on Friday, reaching $11.82. 1,132,995 shares of the company were exchanged, compared to its average volume of 1,630,026. Dyne Therapeutics, Inc. has a 12 month low of $6.36 and a 12 month high of $47.45. The company has a fifty day moving average of $10.30 and a 200 day moving average of $16.33. The stock has a market cap of $1.34 billion, a PE ratio of -3.32 and a beta of 1.19.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.17). On average, equities research analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.